Edap Tms Sa (FOCL) Stock Price & Analysis
Edap Tms Sa (FOCL) fell 1.74% to USD 4.52 as of June 10, 2026 at 05:03 UTC, according to Nexqual real-time market data.
FOCL last closed at USD 4.6; the session ranged USD 4.5–4.79 on volume of 80,715 shares. Market capitalization is $169.42M, with a 52-week range of USD 1.21–5.05 (NGM). Source: Nexqual, June 10, 2026 at 05:03 UTC.
Key Statistics (as of June 10, 2026 at 05:03 UTC)
| Price | USD 4.52 |
|---|---|
| Change | ▼ 1.74% (down) |
| Previous Close | USD 4.6 |
| Open | USD 4.59 |
| Day Range | USD 4.5 – 4.79 |
| 52-Week Range | USD 1.21 – 5.05 |
| Volume | 80,715 shares |
| Market Cap | $169.42M |
| Exchange | NGM |
Technical Analysis (FOCL)
Nexqual's technical model rates FOCL "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:03 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 64.48 (neutral) |
| vs SMA50 | Above (USD 3.83) |
| MACD | 0.22 (positive) |
Analyst Ratings (FOCL)
Wall Street analysts rate FOCL "Buy" based on 3 analysts, with a mean price target of USD 5.83 (range USD 3–10), per Nexqual as of June 10, 2026 at 05:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 5.83 |
| High Target | USD 10 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (FOCL)
| Next Earnings Date | 2026-08-27 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $17.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.24 vs est -0.22 ▼ miss |
| 2025-12-31 | USD -0.25 vs est -0.16 ▼ miss |
| 2025-09-30 | USD -0.15 vs est -0.26 ▲ beat |
| 2025-06-30 | USD -0.17 vs est -0.16 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financials & Fundamentals (FOCL)
| Total Revenue | $74.07M |
|---|---|
| Revenue Growth (YoY) | +24.80% |
| Gross Margin | +43.41% |
| Operating Margin | -41.36% |
| Profit Margin | -41.70% |
| ROE | -130.47% |
| Debt / Equity | 275.14 |
| Current Ratio | 1.34 |
| Total Cash | $15.01M |
| Total Debt | $27.79M |
| Free Cash Flow | $-10.67M |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financial Health Score (FOCL)
Nexqual rates Edap Tms Sa's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:03 UTC.
| Growth | Mixed — Revenue +4.6% YoY (annual), slow |
|---|---|
| Profitability | Mixed — Gross margin 43%, operating -41% |
| Balance Sheet | Weak — $15M cash vs $28M debt |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -130%, ROA -21.0% |
Ownership (FOCL)
| Insider Ownership | +6.13% |
|---|---|
| Institutional Ownership | +38.87% |
| Shares Outstanding | 37.48M |
| Float | 27.97M |
| Short % of Float | +0.20% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Leadership (FOCL)
Edap Tms Sa is led by Ryan Rhodes (age 63), CEO & Director, per Nexqual as of June 10, 2026 at 05:03 UTC.
| CEO & Director | Ryan Rhodes (age 63) |
|---|---|
| Chief Financial Officer | Kenneth Mobeck (age 54) |
| Executive Vice President of Marketing & Product Management | Steven Annen (age 61) |
| Chief Operating Officer | Carre Emmanuel |
| President of EDAP TMS France | Frederic Pech (age 56) |
Major Backers & Investors (FOCL)
Notable institutional backers of Edap Tms Sa include Soleus Capital Management, L.P., Morgan Stanley, Rock Springs Capital Management, LP, according to Nexqual as of June 10, 2026 at 05:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Soleus Capital Management, L.P. | 19.5% |
| Morgan Stanley | 8.93% |
| Rock Springs Capital Management, LP | 3.68% |
| Flax Pond Capital, LLC | 2.09% |
| Bruce & Co, Inc. | 1.17% |
| Bruce Fund, Inc.-BRUCE FUND | 1.11% |
| UBS Group AG | 0.45% |
| Parkman Healthcare Partners LLC | 0.41% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
From Edap Tms Sa's Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally.
- The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
- It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services.
- In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| IRIX | IRIDEX Corporation | USD 1.12 | ▲ 2.75% |
| ELTK | Eltek Ltd. | USD 8.88 | ▼ 0.11% |
| ICCC | ImmuCell Corporation | USD 9.77 | ▲ 1.66% |
| BGMSP | Bio Green Med Solution Inc. | USD 0.7 | ▲ 0.86% |
| SSKN | Strata Skin Sciences, Inc. | USD 0.12 | ▼ 19.33% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:03 UTC. This page is informational and not investment advice.